Files and links (1)
Published, Version of Record (VoR)CC BY V4.0, Open
Journal article
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
Journal of radiation oncology, v 2(1), pp 63-70
01 Mar 2013
PMID: 23504305
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective The low alpha/beta ratio of prostate cancer suggests that hypofractionated schemes of dose-escalated radiotherapy should be advantageous. We report our experience using stereotactic body radiation therapy (SBRT) for the primary treatment of prostate cancer to assess efficacy and toxicity.
Methods From 2007 to 2010, 70 patients (51 % low risk, 31 % intermediate risk, and 17 % high risk) with localized prostate cancer were treated with SBRT using the CyberKnife system. One-third of patients received androgen deprivation therapy. Doses of 37.5 Gy (n=29), 36.25 Gy (n=36), and 35 Gy (n=5) were administered in five fractions and analyzed as high dose (37.5 Gy) vs. low dose (36.25 and 35 Gy).
Results At a median 27 and 37 months follow-up, the low and high dose groups' median PSA nadir to date was 0.3 and 0.2 ng/ml, respectively. The 3-year freedom from biochemical failure (FFBF) was 100 %, 95.0 % and 77.1 % for the low-, intermediate-and high-risk patients. A dose response was observed in intermediate-and high-risk patients with 72 % vs. 100 % 3-year FFBF for the low and high dose groups, respectively (p=0.0363). Grade III genitourinary toxicities included 4 % acute and 3 % late (all high dose). Potency was preserved in 83 % of hormone naive patients.
Conclusion CyberKnife dose escalated SBRT for low-, intermediate-and high-risk prostate cancer exhibits favorable efficacy with acceptable toxicity.
Metrics
12 Record Views
Details
- Title
- Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
- Creators
- Caspian Oliai - Hahnemann University HospitalRachelle Lanciano - Hahnemann University HospitalBrian Sprandio - Philadelphia CyberKnife CenterJun Yang - Hahnemann University HospitalJohn Lamond - Hahnemann University HospitalSteven Arrigo - Philadelphia CyberKnife CenterMichael Good - Philadelphia CyberKnife CenterMichael Mooreville - Philadelphia CyberKnife CenterBruce Garber - Hahnemann University HospitalLuther W. Brady - Hahnemann University Hospital
- Publication Details
- Journal of radiation oncology, v 2(1), pp 63-70
- Publisher
- Springer Nature
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000218723900010
- Other Identifier
- 991019168306804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology